سعر سيريتايد ديسكس 250/50 مكجم 28 جرعة 2025

Seretide Diskus 250/50 is a GlaxoSmithKline dry-powder inhaler delivering fluticasone propionate 250 micrograms and salmeterol 50 micrograms per dose (28 doses), marketed in Egypt through Modern Pharma, for the regular treatment of asthma.

• Regular treatment of asthma where an inhaled corticosteroid plus long-acting beta2 agonist combination is appropriatePopulation: Adults and adolescents 12 years and olderelectronic medicines compendium (emc), UK
• Maintenance treatment of airflow obstruction and reduction of exacerbations in COPD (US labelling for the 250/50 strength)Population: AdultsDailyMed (U.S. National Library of Medicine)

• Very common: headache, nasopharyngitis. Common: candidiasis of mouth and throat, pneumonia (COPD patients), bronchitis, hypokalaemia, throat irritation, hoarseness/dysphonia, sinusitis, contusions, muscle cramps, traumatic fractures, arthralgia, myalgia. Uncommon: hypersensitivity skin reactions, dyspnoea, cataract, hyperglycaemia, anxiety, sleep disorders, tremor, palpitations, tachycardia, atrial fibrillation, angina.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity to the active substances or to any of the excipients.International label, same formulation · electronic medicines compendium (emc), UK
• US: primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures; severe hypersensitivity to milk proteins.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Not for treating acute asthma symptoms (use a rapid- and short-acting bronchodilator); do not initiate during an exacerbation or significantly worsening/acutely deteriorating asthma; increasing reliever use indicates deterioration and the patient should be reviewed.International label, same formulation · electronic medicines compendium (emc), UK
• Do not stop treatment abruptly because of risk of exacerbation; titrate down under medical supervision.International label, same formulation · electronic medicines compendium (emc), UK
• Systemic corticosteroid effects may occur, particularly at high doses for prolonged periods (adrenal suppression, growth retardation in children, decreased bone mineral density, cataract, glaucoma, rarely psychological/behavioural effects); adrenal crisis risk when switching from oral steroids or under stress; regularly monitor height of children on prolonged treatment.International label, same formulation · electronic medicines compendium (emc), UK

• Beta-adrenergic blockers (selective and non-selective)May weaken or antagonise the effect of salmeterol; avoid unless there are compelling reasons.electronic medicines compendium (emc), UK
• Xanthine derivatives, steroids and diureticsPotentially serious hypokalaemia may result from beta2-agonist therapy; concomitant use may potentiate hypokalaemia.electronic medicines compendium (emc), UK
• Ketoconazole and other potent CYP3A4 inhibitorsKetoconazole increased salmeterol plasma exposure (AUC about 15-fold), with possible QTc prolongation; concomitant use should be avoided unless benefit outweighs the risk of systemic side effects of salmeterol and fluticasone.electronic medicines compendium (emc), UK

• A large amount of data on pregnant women (more than 1000 outcomes) indicates no malformative or feto/neonatal toxicity with salmeterol and fluticasone propionate; animal studies showed reproductive toxicity. Use in pregnancy only if the expected benefit to the mother outweighs any possible risk to the fetus, at the lowest effective fluticasone dose.International label, same formulation · electronic medicines compendium (emc), UK
• Unknown whether salmeterol and fluticasone propionate/metabolites are excreted in human milk (both found in rat milk); a risk to breastfed infants cannot be excluded; decide whether to stop breastfeeding or therapy.International label, same formulation · electronic medicines compendium (emc), UK

• Fluticasone propionate: Glucocorticoid with potent anti-inflammatory action within the lungs, reducing symptoms and exacerbations of asthma with fewer adverse effects than systemic corticosteroids.
• Salmeterol (as xinafoate): Selective long-acting (12 hour) beta2-adrenoceptor agonist with a long side-chain binding to the exo-site of the receptor, giving bronchodilation lasting at least 12 hours.